Welcome to our dedicated page for Zynex news (Ticker: ZYXI), a resource for investors and traders seeking the latest updates and insights on Zynex stock.
Zynex Inc. (ZYXI) is a leader in non-invasive medical technology, specializing in electrotherapy devices, pain management solutions, and advanced patient monitoring systems. This news hub provides investors and industry professionals with essential updates on the company’s latest developments, regulatory milestones, and strategic initiatives.
Access real-time information on Zynex’s FDA clearances, product innovations, and financial performance. Our curated news collection covers earnings reports, partnership announcements, clinical trial outcomes, and market expansion efforts. Stay informed about developments across Zynex Medical’s therapeutic devices, Monitoring Solutions’ cardiac technologies, and Neurodiagnostics’ advancements in neurological care.
This resource is designed for those tracking Zynex’s progress in bringing clinically validated medical devices to market. Discover updates on key focus areas including TENS therapy improvements, laser-based monitoring innovations, and compliance with global medical standards. Bookmark this page for streamlined access to press releases, analyst insights, and objective reporting on Zynex’s role in shaping healthcare technology.
Zynex, a medical technology company, announced it does not expect material revenue changes in 2022 following United Healthcare's decision to switch its prescription coverage. CEO Thomas Sandgaard emphasized that most of Zynex's business comes from out-of-network coverage, minimizing the impact of this shift. The mutual decision to terminate the contract allows Zynex to continue offering its NexWave device as a non-addictive pain solution. A conference call will take place on February 24, 2022, to discuss fourth-quarter and full-year results.
Zynex, Inc. (Nasdaq: ZYXI) announced it will report its fourth quarter and full-year 2021 financial results on February 24, 2022. Management will host a conference call and webcast at 2:15 p.m. MT / 4:15 p.m. ET to discuss these results and provide a corporate update. The company specializes in non-invasive medical devices for pain management and rehabilitation. Interested participants can register for the webcast through the provided link.
Zynex, a medical technology company, announced the addition of post-operative and osteoarthritis knee braces to its product line, enhancing its offerings in pain and rehabilitation. With over 10.4 million knee injuries annually, these braces can reduce pain and improve mobility for patients. The company aims to diversify its revenue and has begun training its nationwide sales force on these new products, which are commonly reimbursed by health insurers. CEO Thomas Sandgaard expressed optimism for the expansion, indicating a strategic focus on orthopedic solutions.
Zynex, Inc. (NASDAQ: ZYXI) reported a strong performance in Q4 2021, achieving an 18% year-over-year order growth and an estimated revenue of $40.0 to $43.0 million. The company expects a significant increase in Adjusted EBITDA, estimating $12.5 to $13.5 million for Q4, marking a 280% year-over-year increase. For 2021, Zynex estimates total revenues between $130.0 and $133.0 million, a rise of 62% to 66% from 2020. The successful acquisition of Kestrel Labs and sales rep productivity enhancement are additional noteworthy achievements.
Zynex, Inc. (NASDAQ: ZYXI) has initiated enrollments in a clinical trial for its fluid monitoring system, CM-1500, aimed at enhancing performance characterization during apheresis blood donation. Conducted at Vitalant Research Institute, the trial will monitor changes in the device's patented Relative Index. The CM-1500 received FDA clearance in February 2020, and the company is focused on building clinical evidence for this technology. Zynex is also preparing for the next-generation device (CM-1600) FDA submission, reinforcing its commitment to innovate in non-invasive monitoring solutions.
Zynex, Inc. (NASDAQ: ZYXI) has filed for a utility patent for its innovative noninvasive sepsis monitor, following a provisional patent application in January 2021. The monitor aims to provide advanced warning of sepsis onset, which affects over 1.7 million adults in the U.S. annually and results in approximately 300,000 deaths. CEO Thomas Sandgaard highlighted the monitor's potential to improve patient outcomes by measuring conditions noninvasively and facilitating timely intervention.
Zynex, Inc. (NASDAQ: ZYXI) announced the submission of a 510(k) application to the FDA for its CM-1600 fluid monitoring system, enhancing the existing CM-1500 model. This next-generation device features wireless connectivity and aims to optimize fluid management in patients at risk of hemorrhagic events. CEO Thomas Sandgaard emphasized its potential for improved patient care. The FDA submission is a critical step in advancing the technology, which promises superior accuracy in monitoring before, during, and after surgeries.
Zynex (NASDAQ: ZYXI) announced the acquisition of Kestrel Labs for approximately $31 million, finalized on December 22, 2021. The deal comprises $16 million in cash and $15 million in Zynex stock. Kestrel Labs specializes in laser-based patient monitoring technologies, including the NiCO CO-Oximeter and HemeOx, both pending FDA clearance. The acquisition aims to enhance Zynex's noninvasive monitoring portfolio, potentially leading to improved patient care by offering continuous and accurate hemoglobin monitoring.
Zynex (NASDAQ: ZYXI) has commenced enrollments for a hemodialysis clinical trial using its CM-1500 fluid monitoring system, which received FDA clearance in February 2020. Conducted at DaVita Clinical Research clinics, the trial aims to assess changes in the device's patented Relative Index during hemodialysis. This initiative seeks to refine Zynex's medical technology and advance its monitoring division. The study targets operating and recovery rooms where fluid balance is crucial, expected to complete enrollments by Q1 2022.
ENGLEWOOD, Colo., Nov. 24, 2021 /PRNewswire/ -- Zynex, a medical technology company, announced its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference. The event will feature presentations from November 22 to December 2, 2021, accessible to registered attendees. One-on-one meetings will take place from November 29 to December 2, with requests managed through Piper Sandler. Zynex specializes in non-invasive devices for pain management and rehabilitation, including its NeuroMove device for stroke recovery.
